Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer

被引：0
|
作者：
Peter A. Fasching
Paul Gass
Lothar Häberle
Bernhard Volz
Alexander Hein
Carolin C. Hack
Michael P. Lux
Sebastian M. Jud
Arndt Hartmann
Matthias W. Beckmann
Dennis J. Slamon
Ramona Erber
机构：
[1] Friedrich Alexander University of Erlangen-Nuremberg,Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen
[2] University of California at Los Angeles,EMN, Erlangen University Hospital
[3] Friedrich Alexander University of Erlangen-Nuremberg,Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine
[4] Friedrich Alexander University of Erlangen-Nuremberg,Biostatistics Unit, Department of Gynecology and Obstetrics, Comprehensive Cancer Center Erlangen
来源：
Breast Cancer Research and Treatment | 2019年 / 175卷
关键词：
Breast cancer; Ki-67; Proliferation; Molecular marker; Prognosis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：617 / 625
页数：8
相关论文
共 50 条
  • [21] Progesterone receptor loss identifies hormone receptor-positive and HER2-negative breast cancer subgroups at higher risk of relapse: a retrospective cohort study
    Sun, Jia-Yuan
    Wu, San-Gang
    Li, Feng-Yan
    Lin, Huan-Xin
    He, Zhen-Yu
    ONCOTARGETS AND THERAPY, 2016, 9 : 1707 - 1713
  • [22] Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer
    Gong, Chang
    Tan, Weige
    Chen, Kai
    You, Na
    Zhu, Shan
    Liang, Gehao
    Xie, Xinhua
    Li, Qian
    Zeng, Yunjie
    Ouyang, Nengtai
    Li, Zhihua
    Zeng, Musheng
    Zhuang, ShiMei
    Lau, Wan-Yee
    Liu, Qiang
    Yin, Dong
    Wang, Xueqin
    Su, Fengxi
    Song, Erwei
    EBIOMEDICINE, 2016, 11 : 199 - 209
  • [23] Ki-67 index value and progesterone receptor status can predict prognosis and suitable treatment in node-negative breast cancer patients with estrogen receptor-positive and HER2-negative tumors
    Arima, Nobuyuki
    Nishimura, Reiki
    Osako, Tomofumi
    Okumura, Yasuhiro
    Nakano, Masahiro
    Fujisue, Mamiko
    Nishiyama, Yasuyuki
    Toyozumi, Yasuo
    ONCOLOGY LETTERS, 2019, 17 (01) : 616 - 622
  • [24] Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
    Regan, Meredith M.
    Pagani, Olivia
    Francis, Prudence A.
    Fleming, Gini F.
    Walley, Barbara A.
    Kammler, Roswitha
    Dell'Orto, Patrizia
    Russo, Leila
    Szoke, Janos
    Doimi, Franco
    Villani, Laura
    Pizzolitto, Stefano
    Oehlschlegel, Christian
    Sessa, Fausto
    Peg Camara, Vicente
    Rodriguez Peralto, Jose Luis
    MacGrogan, Gaetan
    Colleoni, Marco
    Goldhirsch, Aron
    Price, Karen N.
    Coates, Alan S.
    Gelber, Richard D.
    Viale, Giuseppe
    BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (02) : 275 - 286
  • [25] Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer
    Zilenaite-Petrulaitiene, Dovile
    Rasmusson, Allan
    Besusparis, Justinas
    Valkiuniene, Ruta Barbora
    Augulis, Renaldas
    Laurinaviciene, Aida
    Plancoulaine, Benoit
    Petkevicius, Linas
    Laurinavicius, Arvydas
    VIRCHOWS ARCHIV, 2025, 486 (02) : 287 - 298
  • [26] Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index
    Ono, Makiko
    Tsuda, Hitoshi
    Yoshida, Masayuki
    Shimizu, Chikako
    Kinoshita, Takayuki
    Tamura, Kenji
    CLINICAL BREAST CANCER, 2017, 17 (01) : 41 - 47
  • [27] Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials
    Meredith M. Regan
    Olivia Pagani
    Prudence A. Francis
    Gini F. Fleming
    Barbara A. Walley
    Roswitha Kammler
    Patrizia Dell’Orto
    Leila Russo
    János Szőke
    Franco Doimi
    Laura Villani
    Stefano Pizzolitto
    Christian Öhlschlegel
    Fausto Sessa
    Vicente Peg Cámara
    José Luis Rodríguez Peralto
    Gaëtan MacGrogan
    Marco Colleoni
    Aron Goldhirsch
    Karen N. Price
    Alan S. Coates
    Richard D. Gelber
    Giuseppe Viale
    Breast Cancer Research and Treatment, 2015, 154 : 275 - 286
  • [28] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Adachi, Yayoi
    Oze, Isao
    Sawaki, Masataka
    Hattori, Masaya
    Yoshimura, Akiyo
    Kotani, Haruru
    Kataoka, Ayumi
    Sugino, Kayoko
    Horisawa, Nanae
    Ozaki, Yuri
    Endo, Yuka
    Nozawa, Kazuki
    Takatsuka, Daiki
    Iwata, Hiroji
    BREAST CANCER, 2021, 28 (05) : 1087 - 1095
  • [29] Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare
    Mueller, Volkmar
    Fasching, Peter A.
    Nabieva, Naiba
    Fehm, Tanja N.
    Thill, Marc
    Schmidt, Marcus
    Kuehn, Thorsten
    Banys-Paluchowski, Maggie
    Belleville, Erik
    Juhasz-Boess, Ingolf
    Untch, Michael
    Kolberg, Hans-Christian
    Harbeck, Nadia
    Aktas, Bahriye
    Stickeler, Elmar
    Kreuzeder, Julia
    Hartkopf, Andreas D.
    Janni, Wolfgang
    Ditsch, Nina
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 673 - 685
  • [30] Impact of adjuvant endocrine therapy on prognosis in small hormone receptor-positive, HER2-negative early breast cancer
    Yayoi Adachi
    Isao Oze
    Masataka Sawaki
    Masaya Hattori
    Akiyo Yoshimura
    Haruru Kotani
    Ayumi Kataoka
    Kayoko Sugino
    Nanae Horisawa
    Yuri Ozaki
    Yuka Endo
    Kazuki Nozawa
    Daiki Takatsuka
    Hiroji Iwata
    Breast Cancer, 2021, 28 : 1087 - 1095
12345